Background & Aims Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the CMRF distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.
Methods This study included participants with steatotic liver disease (SLD) from five cohorts in Hong Kong, South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.
Results This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions of 0 CMRF ranged from 9.0-26.7% among normal-weight NAFLD, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normal-weight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1000 person-years; p<0.001) but not LREs (2.81 and 2.59 per 1000 person-years; p=0.54) in the HK CDARS cohort.
Conclusions Normal-weight individuals with NAFLD demonstrated a lower distribution of CMRFs, resulting in the incomplete agreement between historical NAFLD and MASLD.
Ethical Compliance For all involved cohorts, the study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the appropriate clinical research ethics committee and/or institutional review board, which provided either written consent or a waiver of informed consent.
Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Grace Lai-Hung Wong, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):353-367. Published online December 1, 2025
Background/Aims Previous studies suggest that hypothyroidism is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and its histological severity, but clinical outcome data are largely lacking. We aimed to study the impact of hypothyroidism on liver-related events (LREs).
Methods Patients with MASLD were identified from a territory-wide registry in Hong Kong during 2000–2024. Thyroid status was determined using diagnosis codes and thyroid function tests. The primary outcome, LRE, was defined as a composite of hepatic decompensation, hepatocellular carcinoma, liver transplantation, and liver-related death.
Results A total of 20,478 patients with MASLD were included in the final analysis (mean age 56.4±13.2 years; 43.9% male). At baseline, 18,178 (88.8%) patients were euthyroid, 598 (2.9%) were hyperthyroid, and 1,702 (8.3%) were hypothyroid. Compared with euthyroid patients, both hyperthyroidism and overt hypothyroidism were associated with cirrhosis. At a median follow-up of 4.8 years, 179 patients developed LREs, and 26 died from liver disease. Compared with patients with normal serum thyroid-stimulating hormone (TSH) levels of 0.4–4 mIU/L, those with subclinical (4–10 mIU/L; adjusted time-dependent cause-specific hazard ratio [aCSHR], 2.49; 95% CI, 1.51–4.13) and overt hypothyroidism (>10 mIU/L; aCSHR, 4.91; 95% CI, 1.56–15.47) had an increased risk of LREs. Time-dependent, but not baseline, TSH and thyroid status were associated with LRE risk.
Conclusions Subclinical and overt hypothyroidism are associated with an increased risk of LREs in a dose-dependent manner. The association with time-dependent but not baseline thyroid status underscores the importance of thyroid monitoring and suggests that correction of hypothyroidism may mitigate LRE risk.
Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):289-304. Published online November 11, 2025
Background/Aims Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Results F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes Na Tian, Tie Xiao, Tianyi Xia, Hai‐Yang Yuan, Michael D. Shapiro, Gregory Y. H. Lip, Cheng‐Han Fanren, Li‐You Lian, Chen‐Xiao Huang, Yi‐Xuan Wei, Giovanni Targher, Christopher D. Byrne, Cheng‐Lv Hong, Shenghong Ju, Ming‐Hua Zheng Alimentary Pharmacology & Therapeutics.2026; 63(1): 70. CrossRef
Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply Xiao‐Dong Zhou, Yusuf Yilmaz, Ming‐Hua Zheng Alimentary Pharmacology & Therapeutics.2026; 63(1): 155. CrossRef
Statins in MASLD: Challenges and Future Xiao-Dong Zhou, Mark D. Muthiah, Ming-Hua Zheng JHEP Reports.2025; : 101372. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
The association of advanced lung cancer inflammation index with non-alcoholic fatty liver disease in NHANES 2017–2020 Lin Cheng, Shumeng Li, Hui Li, Jiafeng You, Mingwei Yu, Guowang Yang Frontiers in Medicine.2025;[Epub] CrossRef
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD Xiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
CXCL12 as a Potential Hub Gene for N-Acetylcysteine Treatment of T1DM Liver Disease Menglong Zhao, Mingzheng Han, Shuaihao Guo, Zhaoxin Tang Biomolecules.2025; 15(2): 176. CrossRef
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue Cancer Science.2025;[Epub] CrossRef
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related complications, and assessing treatment response are crucial. The advantage of simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests and extensive validation in different clinical settings. They have shown reasonable accuracy in diagnosing advanced fibrosis and good performance in excluding the majority of patients with a low risk of liver-related complications. Among patients with elevated serum fibrosis scores, a more specific fibrosis and imaging biomarker has proved useful to accurately identify patients at risk of liver-related complications. Among specific fibrosis blood biomarkers, enhanced liver fibrosis is the most widely utilized and has been approved in the United States as a prognostic biomarker. For imaging biomarkers, the availability of vibration-controlled transient elastography has been largely improved over the past years, enabling the use of liver stiffness measurement (LSM) for accurate assessment of significant and advanced fibrosis, and cirrhosis. Combining LSM with other routinely available blood tests enhances the ability to diagnose at-risk metabolic dysfunction-associated steatohepatitis and predict liver-related complications, some reaching an accuracy comparable to that of liver biopsy. Magnetic resonance imaging-based modalities provide the most accurate quantification of liver fibrosis, though the current utilization is limited to research settings. Expanding their future use in clinical practice depends on factors such as cost and facility availability.
Citations
Citations to this article as recorded by
Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence Baihe Wang, Tingting Ji, Zihao Zhang, Yuyao Duan, Zhiqun Xing, Jiazhi Duan, Songbo Zhao, Yang Jia, Qian Wang Colloids and Surfaces B: Biointerfaces.2026; 257: 115182. CrossRef
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation Leyi Wang, Xue Zhang, Yinggang Li, Min Zhao, Gang Xu, Zhenyu Duan, Qiyong Gong, Kui Luo Journal of Controlled Release.2026; 390: 114522. CrossRef
Prediction of major liver-related events in the population using prognostic models Fredrik Åberg, Ville Männistö Gastroenterology Report.2025;[Epub] CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease Jimmy Che-To Lai, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel A Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jerome Boursier, Jose Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocìo Gallego-Du Gut.2025; 74(12): 2050. CrossRef
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD Yu Shi, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Calleja, Victo Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Endohepatology in the Management of Liver Diseases Thomas J. Wang, Ajaypal Singh Seminars in Liver Disease.2025; 45(04): 439. CrossRef
Letter to the Editor: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias Heechul Nam, Sung Won Lee Hepatology.2025;[Epub] CrossRef
Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions Said A. Al-Busafi, Mohammed Eslam Transplantology.2025; 6(4): 35. CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Artificial intelligence (AI)-enabled thermochemical risk modeling via self-attentive deep neural networks for predicting the SADT of organic peroxides Fanzhi Meng, Wei Xu, Yanan Qian, Feng Sun, Bing Sun, Zhe Yang Journal of Loss Prevention in the Process Industries.2026; 99: 105827. CrossRef
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma” Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su Clinical and Molecular Hepatology.2025; 31(1): e101. CrossRef
Prediction Model for Familial Aggregated HBV‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers Linmei Zhong, Guole Nie, Qiaoping Wu, Honglong Zhang, Haiping Wang, Jun Yan Cancer Reports.2025;[Epub] CrossRef
Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma” Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su Clinical and Molecular Hepatology.2024; 30(4): 1016. CrossRef
Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature and poor correlation with liver biochemical markers. Liver histology keeps its role as the standard tool, yet it is well-known for substantial sampling, intraobserver, and interobserver variability. Serum proinflammatory cytokines and apoptotic markers, namely cytokeratin-18, are well-studied with reasonable accuracy, whereas serum metabolomics and lipidomics have been adopted in some commercially available diagnostic models. Ultrasound and computed tomography imaging techniques are attractive due to their wide availability; yet their accuracies may not be comparable with magnetic resonance imaging-based tools. Machine learning and deep learning models, be they supervised or unsupervised learning, are promising tools to identify various subtypes of NAFLD, including those with dominating liver inflammation, contributing to sustainable care pathways for NAFLD.
Citations
Citations to this article as recorded by
Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018 Ming-yu He, Xin-jie Du, Yi-ming Liu BMC Gastroenterology.2025;[Epub] CrossRef
Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease Yunfei Wu, Yan Han, Liming Zheng, Longgen Liu, Wenjian Li, Fan Zhang BMC Gastroenterology.2025;[Epub] CrossRef
Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis Jinwen Chen, Jian Hu, Jialin Zhuang, Zhong Li, Se Peng, Xiaoting Huang, Jialing Zhuang Journal of Clinical Laboratory Analysis.2025;[Epub] CrossRef
Obesity: pathophysiology and therapeutic interventions Yue Kong, Haokun Yang, Rong Nie, Xuxiang Zhang, Fan Zuo, Hongtao Zhang, Xin Nian Molecular Biomedicine.2025;[Epub] CrossRef
The advanced lung cancer inflammation index has an L-shaped association with prognosis in American adults with metabolic dysfunction-associated fatty liver disease: a cohort study Yuexia Lu, Shuaipeng Yuan, Huazhao Xu, Jiqi Ouyang, Jinsheng Dong, Xin Jiang, Xiao Shao, Runshun Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
Global Trends in Non-Invasive Techniques for the Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease: A Bibliometric and Visualization Analysis Jing-Wen Cai, Wei-Long Wang, Dong-Ling Lin, Shu-Feng Ren, Qian-Qian Jia, Xiao-Xuan He, Xue-Xia Yang, Wen Cai, Hui Hou Journal of Multidisciplinary Healthcare.2025; Volume 18: 4243. CrossRef
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden Clinical Epigenetics.2025;[Epub] CrossRef
Quantification of 18F-FDG Delivery Rate for Liver Inflammation Using Shortened Dynamic PET Imaging Protocols Xiaoyu Duan, Souvik Sarkar, Victoria Lyo, Sean Romeo, Benjamin A. Spencer, Karen E. Matsukuma, Valentina Medici, Michael T. Corwin, Ramsey D. Badawi, Guobao Wang Journal of Nuclear Medicine.2025; 66(11): 1834. CrossRef
ChatGPT improves usability, effectiveness, scalability, interpretability and accessibility, in early diagnosis of metabolic dysfunction-associated fatty liver disease Xiaoying Zhou, Zhipeng Gao, Han Ma, Jiahui Hu, Chengfu Xu, Zhe Shen, Miaomiao Tan, Chaohui Yu BMC Gastroenterology.2025;[Epub] CrossRef
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica Tincopa, Nabil Noureddin, Maral Amangurbanova, Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, Ramzan I Alimentary Pharmacology & Therapeutics.2024; 59(1): 80. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis Marinela Sînziana Tudor, Veronica Gheorman, Georgiana-Mihaela Simeanu, Adrian Dobrinescu, Vlad Pădureanu, Venera Cristina Dinescu, Mircea-Cătălin Forțofoiu Metabolites.2024; 14(4): 198. CrossRef
Editorial: Inflammation and chronic disease Frank A. Orlando, Arch G. Mainous Frontiers in Medicine.2024;[Epub] CrossRef
Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis Shaofang Chen, Danping Zhuang, Qingyun Jia, Bing Guo, Genwen Hu Biomaterials Research.2024;[Epub] CrossRef
Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis Xin Zhang, Jiangguo Li, Li Jiang, Yuexia Deng, Licheng Wei, Xing Li Clinical and Experimental Medicine.2024;[Epub] CrossRef
The Metabolomic Footprint of Liver Fibrosis Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle Cells.2024; 13(16): 1333. CrossRef
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model Marwa Matboli, Ibrahim Abdelbaky, Abdelrahman Khaled, Radwa Khaled, Shaimaa Hamady, Laila M. Farid, Mariam B. Abouelkhair, Noha E. El-Attar, Mohamed Farag Fathallah, Manal S. Abd EL Hamid, Gena M. Elmakromy, Marwa Ali Lipids in Health and Disease.2024;[Epub] CrossRef
Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH Anja Schmidt-Christensen, Gustaw Eriksson, William M. Laprade, Behnaz Pirzamanbein, Maria Hörnberg, Kajsa Linde, Julia Nilsson, Mark Skarsfeldt, Diana J. Leeming, Rajmund Mokso, Mariana Verezhak, Anders Dahl, Vedrana Dahl, Kristina Önnerhag, Massoud Rezae Scientific Reports.2024;[Epub] CrossRef
Polygala japonica Houtt.: A comprehensive review on its botany, traditional uses, phytochemistry, pharmacology, and pharmacokinetics Hai-Peng Tang, En-Lin Zhu, Qian-Xiang Bai, Shuang Wang, Zhi-Bin Wang, Meng Wang, Hai-Xue Kuang Fitoterapia.2024; 179: 106233. CrossRef
Chondroitin Sulfate from Halaelurus burgeri Skin Inhibits Hepatic Endoplasmic Reticulum Stress and Inflammation, and Regulates Gut Microbiota Zhaocai Ren, Shang Gao, Shiwei Hu, Sichun Chen, Wei Jiang, Yaming Ge Molecular Nutrition & Food Research.2024;[Epub] CrossRef
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Miwa Kawanaka, Yoshihiro Kamada, Hirokazu Takahashi, Michihiro Iwaki, Ken Nishino, Wenli Zhao, Yuya Seko, Masato Yoneda, Yoshihito Kubotsu, Hideki Fujii, Yoshio Sumida, Hirofumi Kawamoto, Yoshito Itoh, Atsushi Nakajima, Takeshi Okanoue, Takumi Kawaguchi, Gastro Hep Advances.2024; 3(8): 1120. CrossRef
Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef
MASLD: predictive value for liver-related events and extra-hepatic complications Mohamad Jamalinia, Amedeo Lonardo Expert Review of Gastroenterology & Hepatology.2024; 18(11): 685. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean‐Francois Gautier, Angélique Brzustowski, Pierre Bedossa, Laurent Castera, Stanislas Pol, Dominique Valla Alimentary Pharmacology & Therapeutics.2023; 58(9): 888. CrossRef
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B” Soon Kyu Lee The Korean Journal of Gastroenterology.2025; 85(3): 245. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Exploration of Digestive Diseases.2024; : 175. CrossRef
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Victor Pântea, Gheorge Placinta, Scott J. Cotler, Andrew Vaillant, Harel Dahari Hepatology Communications.2023;[Epub] CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus Daniel G. Sausen, Oren Shechter, William Bietsch, Zhenzhen Shi, Samantha M. Miller, Elisa S. Gallo, Harel Dahari, Ronen Borenstein International Journal of Molecular Sciences.2022; 23(24): 15973. CrossRef
Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Clin Mol Hepatol 2022;28(1):77-90. Published online November 5, 2021
Background/Aims We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.
Methods The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.
Results Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).
Conclusions We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.
Preclinical studies on the antitumor and non‐toxic effect of combining pirfenidone with vinorelbine and carboplatin in non‐small cell lung cancer Helena Branco, Catarina A. Rodrigues, Júlio Oliveira, Nuno Mendes, Catarina Antunes, Irina Amorim, Lúcio L. Santos, M. Helena Vasconcelos, Cristina P. R. Xavier International Journal of Cancer.2025; 156(9): 1756. CrossRef
Phase-dependent hepatotoxicity of Aluminum oxide nanoparticles mediated through the intestinal microbiota Mingshu Li, Fuchang Deng, Li Dong, Xiaona Wang, Haiyan Jiang, Siyu Yao, Yuanyuan Chen, Lian Duan, Huamao Du, Guangqiu Qin, Song Tang Environment International.2025; 198: 109398. CrossRef
Parenclitic network mapping predicts survival in critically ill patients with sepsis Emily Ito, Tope Oyelade, Matthew Wikner, Jinyuan Liu, Watjana Lilaonitkul, Ali R. Mani Physiological Reports.2025;[Epub] CrossRef
The role of urea in pathological conditions O.B. Kvasnytska, A.I. Gozhenko, D.D. Ivanov, O.O. Popadynets KIDNEYS.2025; 14(3): 251. CrossRef
An RFH-NPT-based nomogram for predicting the long-term survival of liver cirrhosis patients: a multicenter study Chengbin Zhu, Yuchao Wu, Fulian Zhao, Ruojing Wang, Qijuan Zang, Zhe Jiao, Yage Zhu, Taotao Yan, Juan Du, Li Zhu, Weimin Li, Yongqin Li, Qing Fan, Anping Wu, Xiaodan Liu, Dianzu Liu, Xianmei Tang, Xiaoxiao Xu, Huaying Liao, Yu Li, Yingren Zhao, Yingli He, European Journal of Clinical Nutrition.2025;[Epub] CrossRef
Colchicine induces developmental defects and renal toxicity in zebrafish by upregulating the oxidative stress Fang Chen, Haiyan Wei, Dalong Liao, Yong Huang, Yijian Chen, Huiqiang Lu, Rong Xu Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology.2025; 298: 110328. CrossRef
Neurological alterations in adult female rats developmentally exposed to a glyphosate-based herbicide: Potential role of the immune system Cristina Eugenia Gallegos, Mariana Bartos, Fernanda Gumilar, Diego Nicolás Nabaes Jodar, Ileana Lencinas, Cristina Bras, Betina Noemí García, Jorge Andrés Delbés, Sergio Dominguez, Carlos Javier Baier Toxicology.2025; 518: 154279. CrossRef
Inverse Association Between METS-IR and Lung Cancer Risk: The Role of BMI in a Nationwide Korean Cohort Bo-Kyung Shine, In Hwa Jeong, Minkook Son, Bongjo Kim, Sang Yi Moon, Jong Yoon Lee, Hye Ryeon Kim, Seok Jae Huh Cancers.2025; 17(23): 3727. CrossRef
ULTRASONOGRAPHIC INDICATORS OF THE KIDNEYS IN COMBINED LIVER AND KIDNEY PATHOLOGY IN DOGS V. Rudyashko Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology.2025; 26(2): 216. CrossRef
Advances in Electrochemical Urea Biosensors: Trends and Future Prospects Samar Shurbaji, Arshad Khan, Mohammad K. Hassan, Amine Bermak, Wen‐Di Li, Kabir H Biswas, Bo Wang Advanced Sensor Research.2025;[Epub] CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient‐Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins Mona Mansouri, Astha Lamichhane, Dola Das, Federico Aucejo, Hossein Tavana, Nic D. Leipzig Advanced Biology.2024;[Epub] CrossRef
The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection Nathan E. Timbrell British Journal of Biomedical Science.2024;[Epub] CrossRef
The Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection Anwar Aiad Gaber, Jawad Kadhum Muraih Biomedical and Pharmacology Journal.2024; 17(1): 461. CrossRef
Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats Serdar Vanli, Firuze Kurtoglu, Beyza S. Alan, Gokhan Akcakavak, Ozgur Ozdemir Toxicology Mechanisms and Methods.2024; 34(7): 750. CrossRef
Association of blood urea nitrogen with all-cause and cardiovascular mortality in hyperlipidemia: NHANES 1999–2018 Jing Shen, Zhen Wang, Yong Liu, Tao Wang, Xiao-Yu Wang, Xin-Hui Qu, Zhi-Ping Chen, Xiao-Jian Han Lipids in Health and Disease.2024;[Epub] CrossRef
Association between serum vitamin D status and severity of liver cirrhosis: implications for therapeutic targeting in Nigerian patients Winnifred Njideka Adiri, Bruno Basil, Chinwe Philomena Onyia, Promise Asogwa, Oluchi Joy Ugwuanyi, Olive Obienu, Uchenna Nkemdilim Ijoma, Slyvester Chuks Nwokediuko BMC Gastroenterology.2024;[Epub] CrossRef
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong Hepatology.2023; 77(2): 573. CrossRef
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, Henry Lik‐Yuen Chan, Stephen Lam Chan, Alice Pik‐Shan Kong, Grace Lai‐Hung Wong, Vinc Alimentary Pharmacology & Therapeutics.2023; 57(10): 1103. CrossRef
Effects of the in-utero dicyclohexyl phthalate and di-n-hexyl phthalate administration on the oxidative stress-induced histopathological changes in the rat liver tissue correlated with serum biochemistry and hematological parameters Duygu Aydemir, Mufide Aydogan-Ahbab, Nurhayat Barlas, Nuriye Nuray Ulusu Frontiers in Endocrinology.2023;[Epub] CrossRef
A comparative multi-level toxicity assessment of carbon-based Gd-free dots and Gd-doped nanohybrids from coffee waste: hematology, biochemistry, histopathology and neurobiology study Halyna Kuznietsova, Natalia Dziubenko, Konstantin Paliienko, Natalia Pozdnyakova, Natalia Krisanova, Artem Pastukhov, Tetiana Lysenko, Marina Dudarenko, Valeriy Skryshevsky, Vladimir Lysenko, Tatiana Borisova Scientific Reports.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Effects of 4G mobile phone radiation exposure on reproductive, hepatic, renal, and hematological parameters of male Wistar rat Rohit Gautam, Sonali Pardhiya, Jay Prakash Nirala, Priyanka Sarsaiya, Paulraj Rajamani Environmental Science and Pollution Research.2023; 31(3): 4384. CrossRef
Is lean non-alcoholic fatty liver disease a distinct entity? Huapeng Lin, Vincent Wai-Sun Wong Hepatology International.2022; 16(2): 254. CrossRef
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Luisa Fürschuß, Florian Rainer, Angela Horvath, Vanessa Stadlbauer Liver International.2022; 42(7): 1702. CrossRef
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Suprabhat Giri, Shivaraj Afzalpurkar, Sunil Kasturi, Dhiraj Agrawal Liver International.2022; 42(7): 1700. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong
Clin Mol Hepatol 2021;27(3):499-509. Published online February 26, 2021
Background/Aims Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients.
Methods Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort.
Results 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70–0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted.
Conclusion A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
Citations
Citations to this article as recorded by
Liver elastography-based risk score for predicting hepatocellular carcinoma risk Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song JNCI: Journal of the National Cancer Institute.2025; 117(4): 761. CrossRef
Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study Yixin Hou, Jianguo Yan, Ke Shi, Xiaoli Liu, Fangyuan Gao, Tong Wu, Peipei Meng, Min Zhang, Yuyong Jiang, Xianbo Wang OncoTargets and Therapy.2024; Volume 17: 215. CrossRef
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults Xue Cong, Shuyao Song, Yingtao Li, Kaiyang Song, Cameron MacLeod, Yujie Cheng, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Yiping Chen, Iona Millwood, Shukuan Wu, Xiaoming Yang, Rebecca Stevens, Junshi Chen, Zhengming Chen, Liming Li, Christia BMC Medicine.2024;[Epub] CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim Hepatology Communications.2023; 7(2): e0011. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi, Hepatology.2023; 77(5): 1746. CrossRef
Prognostic Significance of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score in Hepatocellular Carcinoma Jing Zhou, Daofeng Yang Journal of Hepatocellular Carcinoma.2023; Volume 10: 821. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program Supinya Sono, Jirayu Sae-Chan, Apichat Kaewdech, Naichaya Chamroonkul, Pimsiri Sripongpun, Jason T. Blackard PLOS ONE.2022; 17(6): e0270458. CrossRef
The Age, Gamma-Glutamyl Transpeptidase and Platelet Index: A Novel Noninvasive Model for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Liver Cirrhosis Kai Liu, Zeyu Huang, Suhua Yang, Lin Lin, Shuqin Zheng, Xiujun Zhang, Yuan Xue, Weibin Xie Journal of Hepatocellular Carcinoma.2022; Volume 9: 1057. CrossRef
Surveillance for hepatocellular carcinoma: It is time to move forward Bo Hyun Kim, Yuri Cho, Joong-Won Park Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2021; 27(3): 448. CrossRef
Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter Jimmy Che-To Lai, Anna S.F. Lok Hepatology.2026; 83(1): 11. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States Kevin Pak, Ryan Sachar, Sammy Saab Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Wen-Juei Jeng, Grace Lai-Hung Wong Hepatology Communications.2023; 7(3): e0060. CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef
A global investment case for hepatitis B elimination: a modelling study Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott The Lancet Gastroenterology & Hepatology.2023; 8(10): 932. CrossRef
Correlation between contrast-enhanced ultrasound perfusion parameters and EphB4 expression in hepatocellular carcinoma lesions Chen-ZhuoYa Sheng, Gen-Xin Yao, Xin-Rong Zhang, Dong Li World Chinese Journal of Digestology.2021; 29(18): 1084. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
First
Prev
